<body style="font-family:Calibri; font-size:9pt">Request ID: 143</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify; line-height:94%"><span style="font-family:Verdana; font-style:italic">Presenters: Eric Mallard; Mary Ruisi; Allison Scott Fidler-Lehn</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify; line-height:94%"><span style="font-family:Verdana; font-style:italic">Other attendees:</span><span style="width:7.7pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:85.05pt">&#xa0;</span><span style="font-family:Verdana; font-style:italic">Byron Robinson; Mark Zhang; Shaohui Wang; Julia Xiong; Patricia Soulard; Janet Wang</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify; line-height:94%"><span style="width:85.05pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:85.05pt">&#xa0;</span><span style="font-family:Verdana; font-style:italic">From the TIGIT team: Roseann Waterhouse; Keyvan Tadjalli Mehr</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify; line-height:94%"><span style="width:85.05pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:85.05pt">&#xa0;</span><span style="font-family:Verdana; font-style:italic">Member of the ATSA Supervisory Committee; Susan Herbert</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">To strengthen the leadership position of avelumab in locally advanced / metastatic Urothelial Cancer (LA/m UC), which is approved as monotherapy in 2L and in 1L maintenance, the team recommended a life cycle management strategy focusing on the LA/m setting (discussed, developed and vetted by our UC LCM Steering Committee comprising 6 of the top US and EU KTLs).</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana; text-decoration:underline">DECISIONS</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana; font-style:italic">The decision was taken in presence of Susan Herbert, Chair of the ATSA Supervisory Committee for the Pfizer Alliance.</span></p><p style="margin-top:0pt; margin-left:35.7pt; margin-bottom:3pt; text-indent:-17.85pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.7pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.7pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana; font-weight:bold">The FiH committee approved the proposed strategy and plan and released the budget</span><span style="font-family:Verdana"> for a Merck-sponsored randomized PoC Ph II umbrella study (JAVELIN Bladder Medley) aiming to explore multiple avelumab-based maintenance combinations in LA/m UC, with the following recommendation:</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Further evaluate the value of having an avelumab control arm (ensuring comparable patient population in the different arms and understanding potential different OS from historic data in light of risk of future phase III), and seriously explore the usage of a synthetic control arm, or at minimum, borrow power from the JAVELIN Bladder 100 trial (using propensity score matching)</span><span style="font-family:Verdana; -aw-import:spaces">&#xa0; </span><span style="font-family:Verdana">to innovate in this design, given the non-registrational nature of the trial.</span></li></ul><p style="margin-top:0pt; margin-left:72pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">The final decision will be in the remit of the Oncology Development Unit (head, Klaus Edvardsen).</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Merck-sponsored JAVELIN Bladder Medley Ph II study design:</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Newly diagnosed, previously untreated LA/met UC patients.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Standard induction chemo (gem/cis or gem/carbo) for 4-6 cycles.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Randomization after induction phase into four arms (1:1:1:1, N=62 per arm) for maintenance.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">One stratification factor will be chosen among:</span><ul type="square" style="margin-right:0pt; margin-left:0pt; padding-left:0pt"><li style="margin-left:27.12pt; margin-bottom:3pt; padding-left:8.88pt; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">Best Response to 1L chemo (CR/PR vs SD)</span></li><li style="margin-left:27.12pt; margin-bottom:3pt; padding-left:8.88pt; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">metastatic site at diagnosis of LA/met (visceral vs non-visceral); </span></li><li style="margin-left:27.12pt; margin-bottom:3pt; padding-left:8.88pt; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">PD-L1 expression</span></li></ul></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Avelumab control arm (</span><span style="font-family:Verdana; font-weight:bold">final decision to keep it or not to be made</span><span style="font-family:Verdana">, see above)</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Three combinations groups as starting point:</span><ul type="square" style="margin-right:0pt; margin-left:0pt; padding-left:0pt"><li style="margin-left:27.12pt; margin-bottom:3pt; padding-left:8.88pt; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">Avelumab + sacituzumab govitecan (SG, a first-in-class TROP-2 ADC developed by Immunomedics)</span></li></ul></li></ul><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">SG has showed promising data in UC 2L.</span></p><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">To limit toxicity, SG would be administered for a limited number of cycles (5-6).</span></p><ul type="square" style="margin:0pt; padding-left:0pt"><li style="margin-left:99.12pt; margin-bottom:3pt; text-align:justify; padding-left:8.88pt; font-family:serif; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">Avelumab + M6223 (our internal TIGIT inhibitor Ab).</span></li></ul><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">PoC for anti-TIGIT/PD-L1 combination has been achieved with tiragolumab and atezolizumab showing encouraging Ph II data in a PD-L1 high NSCLC cohort.</span></p><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">TIGIT ligand (PVRL-1- stabilizer of TIGIT) high expression is associated with worse OS to Avelumab in JAVELIN Bladder 100 Biomarkers suggesting TIGIT as a potential mechanism of resistance to Avelumab switch maintenance.</span></p><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">Initiation of this arm will require the determination of the RDE from the M6223 monotherapy Ph I DE study. The initial safety data from the M6223 + bintrafusp alfa DE study (or possibly M6223 + avelumab DE) will also support the dose selection for avelumab +M6223.</span></p><ul type="square" style="margin:0pt; padding-left:0pt"><li style="margin-left:99.12pt; margin-bottom:3pt; text-align:justify; padding-left:8.88pt; font-family:serif; -aw-font-family:'Wingdings'; -aw-font-weight:normal; -aw-number-format:''"><span style="font-family:Verdana">Avelumab + NKTR-255 (IL-15 receptor agonist), </span><span style="font-family:Verdana; font-weight:bold">contingent on</span><span style="font-family:Verdana"> positive signals detected in the pre-clinical studies designed in partnership with Nektar team to address remaining questions in solid tumour model (read-out expected June 2021 at the latest).</span></li></ul><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">Analysis of immune cell gene signatures from JAVELIN Bladder 100 suggest that cell types expressing Fc receptors may contribute to the JAVELIN Bladder regimen outcomes, including NK cells.</span></p><p style="margin-top:0pt; margin-left:108pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana">Unique opportunity to bring the first IL-15/anti-PDx combination to UC patients, in a setting where we believe that innate immunity, and particularly NK cells, contributes to clinical outcomes based on Javelin Bladder 100 Pfizer bioinformatic analysis.</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">IDMC meeting on safety after initial 20 patients (5 per group), pause enrolment until after analysis by IDMC.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Futility analysis will be considered during protocol development.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Primary endpoint will be mPFS (from maintenance start) and secondary end-point OS.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">“Go criteria” (HR &lt;=0.70) designed to be robust enough to give us enough confidence to initiate a pivotal study if it is met.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Long Term Follow-up (LTFU)</span></li></ul><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">The team does not plan for a consultation with FDA prior to submitting the CTA but may request scientific advice in the regions of Europe and Asia prior to submitting the CTA.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Sourcing of:</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">SG planned from the market, as our discussions with Immunomedics was interrupted by the GILEAD acquisition.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">NKTR-255 will require a collaboration agreement with Nektar (they are ready to co-fund the study; we expect them to co-fund 50% of the NKTR-255 combination)</span></li></ul><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Risks are evaluated as standard for such a Ph II LCM program, but with significant scientific speculation to be considered.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; text-align:justify; line-height:115%; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">The PoS for each combination will be determined by the project team based on the standard assessment tool.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">The FiH committee acknowledged that though the EV-302 study (open-label, randomized Ph III study of enfortumab vedotin (EV) + pembro and/or CT vs. CT alone in LA/m UC 1L) is expected to read in Nov 2023, the team is confident that because Javelin 100 UC has set an extremely high hurdle to beat in OS, there is no guarantee that EV + Pembro will do that.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; line-height:115%; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">The FiH committee encourages more ambitious thinking on protecting the avelumab stronghold in UC, i.e. team to strategize how to move avelumab to frontline (induction) treatment.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-indent:-18pt; text-align:justify; line-height:115%; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Example timelines (illustrative only as the availability of combination partner drug and the starting dose for M6223 need to be assessed and factored into the final plan):</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">FSFD (for all groups):</span><span style="width:9.1pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="font-family:Verdana">Aug 2021</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Safety IDMC after 5 pts enrolled per group:</span><span style="width:18.04pt; display:inline-block">&#xa0;</span><span style="font-family:Verdana">Mar 2022</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">KSA for primary analysis:</span><span style="width:28.02pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="font-family:Verdana">Mar 2024</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Final CSR:</span><span style="width:24.84pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="width:36pt; display:inline-block">&#xa0;</span><span style="font-family:Verdana">Jun 2025</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">In case of positive outcome of the Ph II (for 1 or more combination), a pivotal study will be proposed to the DPoC committee for a potential start in 2024 and expected read-out by 2028.</span></li></ul><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Estimated budget (direct cost):</span></p><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Total: </span><span style="width:6.32pt; display:inline-block">&#xa0;</span><span style="font-family:Verdana">~45.6 m€ (~8 m€ in 2021)</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Including SG acquisition cost.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Assuming a contribution ~8 m€ from Nektar.</span></li><li style="margin-left:64.4pt; margin-bottom:3pt; text-align:justify; padding-left:7.6pt; font-family:serif; -aw-font-family:'Courier New'; -aw-font-weight:normal; -aw-number-format:'o'"><span style="font-family:Verdana">Additional saving of up to 8 m€ possible if we secure a supply agreement with Gilead for sacituzumab govitecan.</span></li></ul><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">In addition, a study of the combination with VEGFi XL092 (Exelixis) is planned to be embedded into the XL092 Ph Ib basket study running at Exelixis (external partnership with drug supply deal).</span></p><p style="margin-top:0pt; margin-bottom:3pt; text-align:justify"><span style="font-family:Verdana; text-decoration:underline">ACTIONS</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:3pt; text-indent:-18pt; text-align:justify; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Final decision regarding the inclusion of the avelumab control arm to be taken by the Oncology Development Unit.</span></p><p style="margin-top:0pt; margin-left:36pt; margin-bottom:10pt; text-indent:-18pt; text-align:justify; line-height:115%; -aw-import:list-item; -aw-list-level-number:0;  -aw-list-number-styles:'bullet'; -aw-list-padding-sml:10.85pt"><span style="-aw-import:ignore"><span style="font-family:Wingdings">&#11162;</span><span style="width:10.85pt; font:7pt 'Times New Roman'; display:inline-block; -aw-import:spaces">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></span><span style="font-family:Verdana">Final decision on including the combination with NKTR-255 to be taken by the Oncology Development Unit on the basis of the totality of the scientific evidence to date, including the outcome of the ongoing pre-clinical studies run internally and at Nektar (read-out expected June 2021).</span></p><div align="center" style="margin-right:-0.05pt"></body>